ClinicalTrials.gg
Status unknownNCT05369286Updated May 11, 2022

A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors

A Phase 1 interventional study of "MAX-40279-01" and "Toripalimab" in Solid Tumor, sponsored by Maxinovel Pty., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-05-11.

Sponsored by Maxinovel Pty., Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This include two parts, part 1 is a dose escalation study and part 2 is a dose expansion study.

Read the detailed description

This study is a study of Max-40279-01 in combination with toripalimab in patients with advanced solid tumors. This study includes two Parts, the Part 1 will assess the safety and efficacy of the preset several dose levels of Max-40279-01 and toripalimab, and recommend a dose level of Max-40279-01 combined toripalimab for stage 2. The part 2 is designed to study the efficacy and safety of max-40279-01 combined toripalimab in advanced solid tumors or certain specific tumors.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Maxinovel Pty., Ltd. is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and/or females over age 18
  2. and/or cytologically documented local advanced or solid tumor.
  3. (ECOG) performance status of 0-1.
  4. Expected survival >3 months.
  5. Signed form.

Exclusion criteria

Exclusion Criteria:

  1. Known uncontrolled or symptomatic central nervous system disease.
  2. Adverse events (with exception of alopecia, peripheral sensory neuropathy grade ≤ 2 and those listed in specific exclusion criteria) from any prior anticancer therapy of grade >1 (National Cancer Institute Common terminology Criteria [] v.5.0) at the time of randomization.
  3. Inadequate organ or bone marrow function.
  4. Medical history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested product.
  5. Pregnant or breast-feeding woman.
  6. Known allergies, , or intolerance to Max-40279-01 the of these treatments.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    dose level 1 of max-40279 combined dose level 1 of toripalimab

    "MAX-40279-01" and "toripalimab"

    Drug: "MAX-40279-01" and "Toripalimab"

  • Experimental
    dose level 2 of max-40279 combined dose level 1 of toripalimab

    "MAX-40279-01" and "toripalimab"

    Drug: "MAX-40279-01" and "Toripalimab"

  • Experimental
    dose level 2 of max-40279 combined dose level 2 of toripalimab

    "MAX-40279-01" and "toripalimab"

    Drug: "MAX-40279-01" and "Toripalimab"

  • Experimental
    dose level 3 of max-40279 combined dose level 2 of toripalimab

    "MAX-40279-01" and "toripalimab"

    Drug: "MAX-40279-01" and "Toripalimab"

  • Experimental
    recommend dose of max-40279 combined recommend dose level of toripalimab

    "MAX-40279-01" and "toripalimab"

    Drug: "MAX-40279-01" and "Toripalimab"

Interventions

  • Drug"MAX-40279-01" and "Toripalimab"

    "MAX-40279-01"combined with "Toripalimab"

06

What researchers measure

Primary outcomes

  1. DLTs

    Dose limiting toxicity

    Time frame: 21 days

  2. Incidence of Treatment-Emergent Adverse Events

    Safety and tolerability assessed by incidence and severity of adverse events

    Time frame: 24 months

Secondary outcomes

  1. Subsequent clinical recommended dose

    Subsequent clinical recommended dose

    Time frame: 12 months

  2. Cmax

    Maximum plasma drug concentration of Max-40279

    Time frame: Approximately 6 months

  3. Tmax

    Time to maximum plasma concentration of Max-40279

    Time frame: Approximately 6 months

  4. AUC

    Area under the time-concentration curve of Max-40279

    Time frame: Approximately 6 months

  5. T1/2

    Half-life of Max-40279

    Time frame: Approximately 6 months

  6. The blood concentration of toripalimab

    The blood concentration of toripalimab

    Time frame: Approximately 6 months

  7. ADA

    Anti-drug antibody of toripalimab

    Time frame: 6 months

  8. The efficacy end points: ORR、DCR,PFS,DOR,OS

    Objective response rate,Disease control rate,Progression-free survival,Duration of response,Overall survival

    Time frame: 24 months

  9. the correlation of efficacy and the expression level and mutations of FGFR1OP2, its related proteins and inflammatory factors

    the correlation of efficacy and the expression level and mutations of FGFR1OP2, its related proteins and inflammatory factors

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
  • Institute of The Sixth Affiliated Hospital Sun Yat-sen University
    Guangzhou, Guangdong 510000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2022 (actual). Primary completion is estimated for May 2023, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2022
First posted
May 11, 2022
StartActual
Apr 11, 2022
Primary completionEst.
May 31, 2023
CompletionEst.
Aug 31, 2023
Last update
May 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05369286
Lead sponsor
Maxinovel Pty., Ltd.
Responsible party
Sponsor
First posted
May 11, 2022
Start date
Apr 11, 2022
Primary completion
May 31, 2023 (estimated)
Completion
Aug 31, 2023 (estimated)
Last update
May 11, 2022

Study contacts

Hanying MD Bao, Ph.D
Contact
hybao@maxinovel.com
+86-021-51370693
xiangen MD Lu, Ph.D
study chair · Institute of The Sixth Affiliated Hospital Sun Yat-sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion